Background The primary manifestation of coronavirus disease 2019 (COVID‐19) is
respiratory insufficiency that can also be related to diffuse pulmonary microthrombosis and …

Background Venous thromboembolism (VTE) is a frequent complication of COVID-19, so
that the importance of adequate in-hospital thromboprophylaxis in patients hospitalized with …

Antithrombotic agents reduce risk of thromboembolism in severely ill patients. Patients with
coronavirus disease 2019 (COVID‐19) may realize additional benefits from heparins …

Abstract Coronavirus disease 19 (COVID‐19) is considered a multisystemic disease.
Several studies have reported persistent symptoms or late‐onset complications after acute …

We conducted a systematic review and a meta-analysis to assess the association of
anticoagulants and their dosage with in-hospital all-cause mortality in COVID-19 patients …

The COVID-19 pandemic caused by SARS-CoV-2 is associated with a lower fatality rate
than its SARS and MERS counterparts. However, the rapid evolution of SARS-CoV-2 has …

In the context of the coronavirus disease 2019 (COVID-19) pandemic, the global healthcare
community has raced to find effective therapeutic agents against severe acute respiratory …

The novel coronavirus disease 2019 (COVID‐19) has been reported to affect the
gastrointestinal system with a variety of symptoms, including bleeding. The prevalence of …

Since the first description of COVID-19 infection, among clinical manifestations of the
disease, including fever, dyspnea, cough, and fatigue, it was observed a high incidence of …

Abstract Introduction The Italian Society of Anti-Infective Therapy (SITA) and the Italian
Society of Pulmonology (SIP) constituted an expert panel for developing evidence-based …